Review: Mixed signals from trials concerning pharmacologic prevention of type 2 diabetes mellitus

Kenealy, Tim; Arroll, Bruce
September 2005
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p44
Academic Journal
The article focuses on a study by researcher R. Padwal and colleagues, which reports on the pharmacologic prevention of type 2 diabetes mellitus. The study found that in patients with type 2 diabetes mellitus, some oral hypoglycemic agents and antiobesity drugs reduce the incidence of diabetes, but the findings are inconsistent and many studies have low patient follow-up or show high drug-related gastrointestinal adverse effects. It is concluded that no single agent is a clear choice for preventing diabetes in patients with impaired glucose tolerance.


Related Articles

  • HYPOGLYCEMIC EFFECT OF BAEL PATRA (AEGLE MARMELOS) IN NIDDM PATIENTS. Sankhla, Aarti; Sharma, Shashi; Sharma, Nidhi // Journal of Dairying Foods & Home Sciences;2009, Vol. 28 Issue 3/4, p233 

    The present study attempted to find the efficacy of bael patra in the management on thirty eight NIDDM patients in the age range of 40-60 years. For the purpose, forty subjects from the two diabetic clinics in Ajmer city were selected and divided in to two groups of twenty subjects each taking...

  • Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents. Bretzel, Reinhard G.; Eckhard, Michael; Landgraf, Wolfgang; Owens, David R.; Linn, Thomas // Diabetes Care;Nov2009 Supplement, Vol. 32, pS260 

    The article discusses a study called A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantus once daily or Lispro at mealtime in type 2 diabetic patients failing Oral treatment (APOLLO) trial. It notes that the study showed that a once daily basal insulin...

  • Strategies for insulin impairment. R.M.D. // Cortlandt Forum;2/25/96, Vol. 9 Issue 2, p124 

    Responds to queries on efficacy of prescribing hypoglycemic agents among non-insulin dependent diabetics. Insulin levels; Recommendations for alternative medication regimen including exercise and proper diet.

  • VITAL: Paricalcitol reduced renal, CV risks in patients with diabetic nephropathy.  // Endocrine Today;Jan2011, Vol. 9 Issue 1, p24 

    This article discusses the effectiveness of the combination of paricalcitol and renin-angiotension-aldosterone system inhibition in lowering residual renal risk for patients with type 2 diabetes.

  • Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes. Mizushige, Tomoko; Kobori, Hiroyuki; Nishijima, Yoko; Yano, Yuichiro; Sakata, Koji; Hayakawa, Manabu; Nishiyama, Akira // Journal of Diabetes Research;8/25/2015, Vol. 2015, p1 

    Background. The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D). Methods. In 43 patients with T2D (18 women,...

  • Wide Variation in the Sequence of Medications Prescribed for Glycemic Control. Grant, Richard W.; Wexler, Deborah; Lester, William T.; Nathan, David M.; Meigs, James B. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA315 

    Glycemia remains inadequately controlled in the majority of patients with diabetes. Recent guidelines for type 2 diabetes have recommended a parsimonious treatment algorithm beginning with metformin. Our objective was to characterize current clinical practice among patients prescribed a sequence...

  • SECTION 8: ENDOCRINE SYSTEM.  // MPR - Pharmacist's Edition;Summer2010, Vol. 4 Issue 2, p117 

    The article provides information on the use of insulin for the treatment of diabetes. It cites that insulin is used in type 1 diabetes patients and in type 2 diabetes who cannot control their symptoms using diet or exercise. It notes that insulin is given by subcutaneous injection and has...

  • Effects of Vildagliptin in Subjects with IGT. Rosenstock, J.; Rendell, M. S.; Landin-Olsson, M.; Foley, J. E.; Rochotte, E.; Baron, M. A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA135 

    Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control in patients with type 2 diabetes (T2DM) by increasing α-and β-cell responsiveness to glucose. However, vildagliptin does not influence insulin secretion or glucose tolerance in normoglycemic subjects....

  • Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting. Maru, Shoko; Koch, Gary G.; Stender, Monika; Clark, Douglas; Gibowski, Laura; Petri, Hans; White, Alice D.; Simpson JR., Ross J. // Diabetes Care;Jan2005, Vol. 28 Issue 1, p20 

    OBJECTIVE -- To assess the effects of antidiabetic drugs on the risk of heart failure in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS -- We conducted a retrospective cohort study with a newly diagnosed diabetes cohort of 25,690 patients registered in the U.K. General Practice...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics